Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avacta Group plc ( (GB:AVCT) ) has shared an announcement.
Avacta Therapeutics has appointed Francis Wilson as Chief Scientific Officer, succeeding Michelle Morrow, who is leaving to pursue another opportunity. Wilson, previously Vice President of Chemistry since 2022, has played a key role in advancing Avacta’s pre|CISION® platform and developing the sustained-release mechanism underpinning its FAP-Exd (AVA6103) program, which is expected to enter clinical testing soon.
With a long career in medicinal chemistry at companies including Roche, Xenova, Cellzome and Summit Therapeutics, Wilson brings extensive experience in moving programs from discovery into clinical development. His promotion comes as Avacta prepares for an intensive phase of preclinical development and intellectual property generation, underscoring the strategic importance of its pre|CISION® platform in strengthening the company’s position in the competitive oncology drug development landscape.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £48.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on GB:AVCT Stock
According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on GB:AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics, a division of Avacta Group plc, is a clinical-stage biopharmaceutical company focused on oncology, developing its proprietary pre|CISION® tumor-activated drug delivery platform. The company’s pipeline includes pre|CISION® peptide drug conjugates and Affimer® drug conjugates that aim to deliver highly potent cancer therapies directly to tumor microenvironments while minimizing damage to healthy tissues.
Average Trading Volume: 2,517,497
Technical Sentiment Signal: Sell
Current Market Cap: £264.6M
For detailed information about AVCT stock, go to TipRanks’ Stock Analysis page.